Featured Research

from universities, journals, and other organizations

Lasofoxifene reduces breast cancer risk in postmenopausal osteoporotic women

Date:
November 7, 2010
Source:
Journal of the National Cancer Institute
Summary:
Lasofoxifene statistically reduced the overall risk of breast cancer, as well as ER positive invasive breast cancer in postmenopausal women with low bone density, according to a new study.

Lasofoxifene statistically reduced the overall risk of breast cancer, as well as ER positive invasive breast cancer in postmenopausal women with low bone density, according to a study published online in The Journal of the National Cancer Institute.

Lasofoxifene is a SERM, or selective estrogen receptor modulator, that, like tamoxifen, blocks the effects of estrogen in breast tissue. Another SERM, raloxifene, has been shown to reduce breast cancer risk. In the Postmenopausal Evaluation and Risk-Reduction with Lasofoxifene (PEARL) trial, a double-blind, placebo-controlled, randomized trial, 8556 postmenopausal women with low bone density and normal mammograms were randomly assigned to two doses of lasofoxifene -- either .25 or .50 milligrams of it per day, or placebo.

Lasofoxifene was shown to reduce the risk of estrogen receptor positive breast cancer, but to determine whether lasofoxifene reduced the risks of ER positive invasive breast cancer and total breast cancer, Andrea Z. LaCroix, Ph.D., of the Fred Hutchinson Cancer Research Center, analyzed these effects of lasofoxifene in all 8556 women overall and across baseline characteristics influencing cancer risk, including age, body mass index, Gail score, and levels of serum sex hormones. The 8556 women in the trial were between the ages of 59 and 80, and had osteoporosis. The researchers found that the women taking 0.5 milligrams of lasofoxifene, compared to the placebo, had a statistically significantly reduced risk of total breast cancer by 79%; the risk of ER positive breast cancer was also reduced by 83%. Furthermore, there was a 32% reduction in coronary events, and a 36% reduction in strokes. Vertebral fractures also decreased by 42%, and non-vertebral fractures, by 24%.

The authors say the risk reduction for breast cancer with lasofoxofene was similar to that reported for tamoxifen and raloxifene. At the same time, lasofoxifene did not pose a risk for other cancers, unlike tamoxifen, which is associated with an increased risk of endometrial cancer and other gynecological safety concerns. Raloxifene has also been used less frequently because of its perceived insufficient spectrum of benefits.

Lasofoxifene may therefore have more potential benefits than the other SERMS: "The spectrum of activity for lasofoxifene, including the clinically and statistically significant reductions of non-vertebral fractures, stroke, and serious heart events, makes it an attractive option, particularly for use in postmenopausal women with osteoporosis or higher estradiol levels," the authors write.

They also point out some limitations of the study, namely the small number of incident breast cancer cases, the lack of follow-up data after five years, and the lack of comparative data on the efficacy of lasofoxifene to reduce stroke and other coronary events and fractures compared to other SERMS.

In an accompanying editorial, Victor G. Vogel, MD, of the Geisinger Medical Center, compared the results of the PEARL trial to those in the STAR trial (Study of Tamoxifen and Raloxifene). Women in the former were on average nine years older, and as a probable consequence, they had higher rates of venous thromboembolism.

However, the reductions in breast cancer incidence, and the stroke event rate with lasofoxifene were particularly "dramatic," Vogel writes, adding that lasofoxifene may represent the long-awaited "tipping point" in breast cancer chemoprevention.

"We need more complete information about the long-term effects of lasofoxifene on both beneficial and unfavorable outcomes, but the early data regarding its risks and benefits are encouraging," Vogel writes.


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Andrea Z. Lacroix, Trevor Powles, C. Kent Osborne, Kevin Wolter, John R. Thompson, David D. Thompson, D. Craig Allred, Rσisνn Armstrong, Steve R. Cummings, Richard Eastell, Kristine E. Ensrud, Paul Goss, Andrew Lee, Patrick Neven, David M. Reid, Madelyn Curto, Slobodan Vukicevic, and on Behalf of the PEARL Investigators. Breast Cancer Incidence in the Randomized PEARL Trial of Lasofoxifene in Postmenopausal Osteoporotic Women. JNCI J Natl Cancer Inst, November 4, 2010 DOI: 10.1093/jnci/djq415

Cite This Page:

Journal of the National Cancer Institute. "Lasofoxifene reduces breast cancer risk in postmenopausal osteoporotic women." ScienceDaily. ScienceDaily, 7 November 2010. <www.sciencedaily.com/releases/2010/11/101104171343.htm>.
Journal of the National Cancer Institute. (2010, November 7). Lasofoxifene reduces breast cancer risk in postmenopausal osteoporotic women. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2010/11/101104171343.htm
Journal of the National Cancer Institute. "Lasofoxifene reduces breast cancer risk in postmenopausal osteoporotic women." ScienceDaily. www.sciencedaily.com/releases/2010/11/101104171343.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) — A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) — The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) — The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) — Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:  

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile iPhone Android Web
          Follow Facebook Twitter Google+
          Subscribe RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins